Long acting GLP-1 receptor agonist (injectable)
Taspoglutide 30 mg injection once weekly
TASP_SC_30MG_QW
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.62 (0.01 to 41.72) | 0.44 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 2.67 (0.42 to 17.07) | 0.31 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.24 (0.00 to 5.57) | 0.75 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 7.66 (3.32 to 17.54) | 0.14 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 16.84 (5.06 to 59.77) | 0.07 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.58 (0.83 to 7.92) | 0.31 |